about
Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of ViewA circulating permeability factor in focal segmental glomerulosclerosis: the hunt continuesUrokinase gene 3'-UTR T/C polymorphism is associated with malignancy and ESRD in idiopathic membranous nephropathy.Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuriaSignificance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.Novel biomarkers in glomerular disease.Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malariaThe role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptorFocal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist.An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases.Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.The glomerular permeability factors in idiopathic nephrotic syndrome.Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?Novel Biomarkers for Renal Diseases? None for the Moment (but One).FSGS: from pathogenesis to the histological lesion.Genetics of childhood steroid-sensitive nephrotic syndrome.Focal Segmental Glomerulosclerosis.What are we missing in the clinical trials of focal segmental glomerulosclerosis?Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients.Circulating factor in FSGS: a black sheep in the suPAR family?Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.The intriguing role of soluble urokinase receptor in inflammatory diseases.Meeting report of the 2017 KidGen Renal Genetics Symposium.Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese.Rho-GTPase Signalling in the Pathogenesis of Nephrotic Syndrome
P2860
Q26738374-EE3733B3-4C32-4D09-B2D8-116DE121172CQ26776389-B5F3B7FB-810A-4853-A839-A6A3A7773010Q33562449-9E7AFE11-9153-4F9A-A080-FD567D2E87C5Q33974535-7845D82C-AA71-4BCC-A98B-9775152894A5Q34760971-D3191668-B046-4184-9CC1-65A951C66296Q36549551-6C53080C-D44D-4472-BAC5-80962B6BBB58Q37658483-3B5252C6-60B2-4B26-83CC-9B55174FF28FQ37716666-D9B6E701-9F80-455A-8986-E4966A7A8F7DQ38152259-03A56285-3CE3-49B0-978B-C1D09002ABFAQ38164339-CD28199F-D4E7-4B5D-8DAB-ECEF8E05860CQ38192853-F7D90855-39EC-4E51-815E-32B6B23F76BFQ38232593-7D980313-C7A5-4923-8001-2BAC52C6636DQ38270521-5F1B503E-0FC8-4615-A1E9-5D122D90A2B6Q38449629-D13F9C7B-EF6B-4C07-AEEA-D3098913E075Q38458152-FF33E753-0C3F-4608-8F4F-A6E4C71C3FF4Q38763898-D8C97C0F-598B-4B8F-9D17-FACC4547F8A8Q38890561-DA1B6978-5362-4C44-A968-1733418AEE1BQ38911915-6B4393D5-80D5-46E2-B62E-72BBC066E6B5Q38938623-3617E292-4322-4298-ABBD-AEE70C5E1B73Q39229298-95B4B5E0-D4EF-46C4-A8A3-8E8C87B3D559Q39394149-145F9CFB-CC3F-4110-ADBA-D302FA5B1DB4Q42746390-7F7984EB-EC3E-421D-94D8-3DFE081540F2Q43239317-EF6AE785-C356-4D89-844F-5DDC9FE8CE87Q49124480-5D32113E-817B-4C33-9AE5-DE02F0765088Q49491268-04EB9913-5AA5-4011-B66C-FF080F1DAE1FQ53663523-1D0340E3-65B1-45FF-A90A-F721A6FB3C39Q59052275-4227D906-5B2D-489C-B81F-3DEF93D33B6B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Serum suPAR in patients with FSGS: trash or treasure?
@en
type
label
Serum suPAR in patients with FSGS: trash or treasure?
@en
prefLabel
Serum suPAR in patients with FSGS: trash or treasure?
@en
P2093
P2860
P1433
P1476
Serum suPAR in patients with FSGS: trash or treasure?
@en
P2093
Jack F M Wetzels
Jeroen K J Deegens
Rutger J H Maas
P2860
P2888
P304
P356
10.1007/S00467-013-2452-5
P577
2013-03-21T00:00:00Z
P6179
1006085225